Archives — January 2012 back to current month (2)
It may seem counterintuitive that rare diseases might actually be biotech growth drivers, but Senior Analyst and Managing Director Geoff Meacham of JPMorgan Chase makes just that case. In this exclusive interview with The Life Sciences Report, Meacham lays out his premise that hepatitis C and orphan disease drugs can cure the woes of growth-starved investors.
The 2012 Biotech Showcase investor conference in San Francisco drew a record number of life science interests from all over the world.
|"We view RVX's shares as undervalued, and in a position to provide long-term upside potential."|
|"INO announced a collaboration with Roche to evaluate their DNA-based immunotherapies in advanced bladder cancer."|